[HTML][HTML] Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
Journal of clinical oncology, 2013•ncbi.nlm.nih.gov
Purpose In phase I/II trials, the cytotoxic T lymphocyte–associated antigen-4–blocking
monoclonal antibody tremelimumab induced durable responses in a subset of patients with
advanced melanoma. This phase III study evaluated overall survival (OS) and other safety
and efficacy end points in patients with advanced melanoma treated with tremelimumab or
standard-of-care chemotherapy.
monoclonal antibody tremelimumab induced durable responses in a subset of patients with
advanced melanoma. This phase III study evaluated overall survival (OS) and other safety
and efficacy end points in patients with advanced melanoma treated with tremelimumab or
standard-of-care chemotherapy.
Abstract
Purpose
In phase I/II trials, the cytotoxic T lymphocyte–associated antigen-4–blocking monoclonal antibody tremelimumab induced durable responses in a subset of patients with advanced melanoma. This phase III study evaluated overall survival (OS) and other safety and efficacy end points in patients with advanced melanoma treated with tremelimumab or standard-of-care chemotherapy.
ncbi.nlm.nih.gov